In 1981, the first published reports of what would become known as AIDS offered a clinical description of a mysterious and devastating illness. They documented what physicians were seeing in their patients, but, as Anthony Amoroso, MD, professor of medicine at University School of Medicine(UMSOM), Director, Institute of Human Virology (IHV) Clinical Community Health Programs and Director, IHV Clinical Innovation Programs, reflects four and a half decades later, they could not capture the full human experience of an emerging epidemic defined by fear, stigma, and uncertainty.

“There was enormous fear. There was enormous stigma,” says Dr. Amoroso. The stigma extended beyond individuals to families, churches, hospitals, and entire communities, shaping how people understood the disease and whether they sought care.

Even as scientists worked to identify the cause of AIDS and develop effective treatments, fear created barriers that medicine alone could not overcome. People delayed testing, avoided treatment, and sometimes struggled to tell even their closest loved ones about their diagnosis.

For Dr. Amoroso, those early lessons remain essential to understanding HIV today: scientific progress can transform what is possible, but its impact depends on whether people can access, trust, and benefit from it.

As IHV celebrates its 30th year, that principle is woven into the institute’s history and its continuing mission to translate scientific discovery into meaningful improvements in human health.

Learning From the Realities of the Epidemic

When Dr. Amoroso arrived in Baltimore in 1998, he had already trained in Boston, where he had cared for patients with HIV. But the scale and severity of the epidemic he encountered in Baltimore left a lasting impression.

Patients were arriving at hospitals with life-threatening opportunistic infections, often at advanced stages of AIDS. Physicians worked to stabilize them with the best treatments available, then sent them home with plans to continue their care in outpatient clinics. Too often, those plans fell apart.

He began investigating what happened after patients left the hospital. In one early analysis, he found that only 13% of patients discharged after treatment for a life-threatening opportunistic infection attended their scheduled clinic appointment.

The finding exposed a troubling disconnect. Patients could receive excellent hospital care, yet still be unable to sustain the treatment and follow-up needed to survive.

“We had the access, but we just couldn’t get our patients to see us,” Dr. Amoroso recalls.

The problem challenged the conventional understanding of access to care. Baltimore had knowledgeable clinicians, strong medical institutions, and access to antiretroviral medications. Yet those resources were not consistently translating into better outcomes for the people who needed them most.

He began to see that providing care was not enough. Health systems also had to understand the circumstances, experiences, and concerns of the communities they served. Care needed to be delivered in ways that encouraged people to return, remain engaged, and trust the institutions responsible for their health.

That realization helped shape Dr. Amoroso's approach to HIV research and clinical practice, moving beyond the immediate needs of individual patients toward broader questions about public health, continuity of care, and how to make treatment effective over the long term.

From Measuring the Virus to Transforming Treatment

The scientific advances of the past four decades have dramatically changed the outlook for people living with HIV. Dr. Amoroso points to one breakthrough that he believes deserves particular recognition: the development of HIV viral load testing.

Before viral load measurements became clinically available in the mid-1990s, physicians relied heavily on CD4 counts to monitor patients' immune health. They could see when a patient's condition deteriorated, but they had fewer tools to understand how effectively treatment was controlling the virus itself.

The ability to measure HIV in the blood changed that equation. Clinicians could monitor viral replication, assess whether medications were working, and better understand how treatment failure and drug resistance developed. That knowledge helped guide the evolution toward more effective combination therapies.

For Dr. Amoroso, this is a powerful example of translational science at work: a scientific advance that changes not only what researchers know, but also what physicians can do for patients.

It is also part of what drew him to IHV. He joined the institute motivated by the promise of HIV vaccine research and the opportunity to contribute to a major scientific challenge.

“It was a big mission,” he says, describing the vaccine effort as something of a moonshot. “It was good for the soul to work on something like that.”

IHV and researchers around the world invested years of effort in understanding antibodies that could neutralize HIV and potentially inform vaccine development. Although those efforts have not yet delivered an effective preventive vaccine, they have deepened scientific understanding of the virus and the challenges involved in preventing infection.

The path to a cure has likewise proved to be a challenge. Yet Dr. Amoroso emphasizes that the pharmaceutical advances made alongside vaccine and cure research represent an extraordinary success. HIV treatment has evolved from early, limited options to highly effective therapies that can suppress the virus and allow people to live longer, healthier lives.

The challenge now is to build on that success while continuing to pursue the scientific breakthroughs that remain elusive.

The Next Frontier: Making Prevention Work for Everyone

Today, Dr. Anthony Amoroso sees tremendous promise in new approaches to HIV prevention, including long-acting medications that can reduce the burden of taking daily pills. These developments offer new opportunities to reach people who might benefit from prevention but face practical or personal barriers to using existing options.

But the central question has evolved. It is no longer only whether science can produce effective tools. It is whether health systems can deliver them consistently, affordably, and evenly.

“We have the tools, you know, we have the science, we have the tools to prevent HIV,” he says.

What remains is the challenge of implementation: building the clinical infrastructure, funding mechanisms, and trusted relationships needed to make prevention accessible at scale.

That challenge is particularly visible in Baltimore, where Dr. Amoroso has spent much of his career. He has seen how successful public health approaches developed through international HIV programs can offer valuable lessons for local care. He has also seen how difficult it can be to adapt those approaches to the U.S. healthcare system, where insurance requirements, funding, and gaps in public health infrastructure can stand in the way.

For him, the comparison underscores the importance of learning across communities and borders. The experience gained through IHV's international work can inform efforts at home, just as lessons from Baltimore have contributed to HIV programs abroad.

Dr. Amoroso is encouraged by growing interest in prevention and the referrals he is seeing for pre-exposure prophylaxis, or PrEP. He believes these developments signal meaningful progress, even as significant barriers remain.

“I think there’s tremendous hope,” he says. “We just have some hills to climb in the prevention world, but we’ll get there.”

Thirty years of IHV and the Work Ahead

As IHV marks three decades since its founding, Dr. Amoroso's reflections offer a reminder of what sustained scientific commitment can accomplish and what it takes to turn discovery into lasting change.

The institute's history is part of a much larger story: researchers working to understand a virus, clinicians finding better ways to treat patients, and public health teams building programs to reach communities across the globe. That work has contributed to remarkable advances, even as persistent disparities remind us that progress is not experienced equally by everyone.

The earliest AIDS reports documented a medical crisis whose full dimensions were still unknown. Forty-five years later, the scientific understanding of HIV has advanced enormously. Yet the lessons he draws from those early years remain relevant: fear and stigma can undermine effective interventions, access must mean more than the availability of a clinic or medication, and even the most promising scientific tools must be delivered in ways that people can trust.

For IHV, these lessons reinforce the importance of bringing research, clinical care, and public health together. They also point toward the next chapter of HIV work — one in which expanding access to effective prevention and treatment is as important as continuing to push the boundaries of discovery.

The first reports of AIDS marked the beginning of a long and difficult journey. Forty-five years later, that journey continues, shaped by extraordinary scientific progress and an enduring responsibility to the people and communities most affected.

As IHV celebrates its 30th anniversary, Dr. Amoroso's message is ultimately one of persistence and possibility: the tools are improving, the knowledge is growing, and the opportunity to make a difference remains. The task ahead is to ensure that the benefits of those advances reach everyone who needs them.